Purpose: We aimed to investigate the potential of [Ga]Ga-FAPI-04 PET/CT as an alternative diagnostic and theranostic tool in well-differentiated NETs refractory to [Lu]Lu-DOTATATE therapy.
Methods: Patients who received at least two cycles of [Lu]Lu-DOTATATE therapy for metastatic NETs and progressed under treatment were included. All patients had performed [Ga]Ga-DOTATATE and [Ga]Ga-FAPI-04 PET/CT within 3 weeks. The number of PET-positive lesions related to NETs and tumor sites was documented. Mann-Whitney U and chi-square tests were used to compare SUVmax levels of tracers and the number of detected metastases.
Results: Twelve patients (7 male, 5 female) who met the eligibility criteria were included in the study. Ten patients had grade 1-2 NET of various origins, and two had paraganglioma and pheochromocytoma. One hundred ninety-eight of 230 lesions (86%) were SSTR positive with a median SUVmax of 16.6 (2.2-76.5), and 88 of 230 lesions (38.2%) were [Ga]Ga-FAPI-04 positive with a median SUVmax of 5.1 (2.3-21). Median SUVmax level and detected number of tumors were significantly higher in [Ga]Ga-DOTATATE PET/CT (p=<0.001). [Ga]Ga-FAPI-04 PET/CT was completely (n:2) or almost completely (n:3) negative in 5 (42%) patients. Two (17%) patients had flip-flop SSTR/FAPI uptake in tumors. In four patients (33%), tumor uptake or the number of PET-positive lesions was inferior in [Ga]Ga-FAPI-04 PET/CT. In only one patient (8%), tumor uptakes were higher in [Ga]Ga-FAPI-04 PET/CT. Low-dose [Lu]Lu-FAPI-46 dosimetry was performed on the FAPI-dominant patient; absorbed radiation doses per GBq were 1.26 Gy, 0.36 Gy, 0.32 Gy, and 0.2 Gy for kidneys, liver, spleen, and total body, respectively. The mean absorbed dose per GBq was 0.33 Gy for liver mass and 0.41 Gy for metastatic lymph nodes.
Conclusion: Our preliminary results demonstrated that [Ga]Ga-FAPI-04 PET/CT mainly failed in well-differentiated NETs refractory to [Lu]Lu-DOTATATE therapy and had a limited role as an alternative diagnostic or theranostic agent. Further investigations with a larger patient population are required to determine the impact of [Ga]Ga-FAPI-04 PET/CT on NETs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-023-06497-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distinguishing benign from malignant lesions with high [ Ga]Ga-FAPI-04 uptake in oncology patients: Insights from dynamic total-body [ Ga]Ga-FAPI-04 PET/CT.
Eur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, 200127, China.
Background And Purpose: While [ Ga]Ga-FAPI-04 PET/CT is widely used in various malignant tumors diagnosis, its specificity is challenged by high uptake in benign lesions such as inflammatory lymphadenopathy, bone fractures, and degenerative changes. This study aimed to quantitatively assess and characterize the metabolic heterogeneity of [ Ga]Ga-FAPI-04 uptake in benign and malignant lesions using dynamic total-body PET/CT.
Methods: Dynamic total-body [ Ga]Ga-FAPI-04 PET/CT scans (0-60 min post-injection) were performed on 17 oncology patients.
Targeting FAP-positive chondrocytes in osteoarthritis: a novel lipid nanoparticle siRNA approach to mitigate cartilage degeneration.
J Nanobiotechnology
October 2024
Department of Surgery of Spine and Spinal Cord, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, No.7 Weiwu Road, Zhengzhou, Henan Province, 450003, China.
Background: Osteoarthritis (OA) is a common joint disease that leads to chronic pain and functional limitations. Recent research has revealed soluble fibroblast activation protein (FAP) secreted from OA synovium could degrade type II collagen (Col2) in cartilage to promote the progression of OA. This study aimed to reveal the role of FAP from chondrocytes in OA and develop a novel lipid nanoparticle (LNP)-FAP siRNA delivery system for OA treatment.
View Article and Find Full Text PDF[ Ga]Ga-FAPI-04 PET/CT may be a predictor for early treatment response in rheumatoid arthritis.
EJNMMI Res
January 2024
Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, China.
Background: The identification of biomarkers predicting the treatment response of rheumatoid arthritis (RA) is important. [ Ga]Ga-FAPI-04 showed markedly increased uptake in the joints of patients with RA. The purpose of this study is to investigate whether [ Ga]Ga-FAPI-04 PET/CT can be a predictor of treatment response in RA.
View Article and Find Full Text PDFComparing the clinical value of baseline [ Ga]Ga-FAPI-04 PET/CT and [F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis.
Eur J Nucl Med Mol Imaging
November 2023
Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine and State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science and PUMC, No. 1 Shuaifuyuan, Wangfujing Street, Dongcheng District, Beijing, 100730, China.
Purpose: Anatomical and molecular staging strategies are needed for the personalized treatment of localized pancreatic ductal adenocarcinoma (PDAC). This study evaluated the performance of [ Ga]Ga-FAPI-04 and [F]F-FDG PET/CT on the disease staging and prognostic value of patients with localized PDAC on contrast-enhanced (CE)-CT images.
Methods: Patients with suspected localized PDAC on CE-CT were recruited for static [ Ga]Ga-FAPI-04 and [F]F-FDG and PET/CT, and select patients underwent simultaneous 60-min dynamic Ga-FAPI-04 PET/CT.
Prognostic value of preoperative [ Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics.
Eur J Nucl Med Mol Imaging
May 2023
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Purpose: Our aim was to assess the prognostic value of [ Ga]Ga-FAPI-04 positron emission tomography (PET) uptake in PDAC and to evaluate the correlation between in vivo lesional radioactivity with pathological characteristics of pancreatic ductal adenocarcinoma (PDAC).
Methods: We retrospectively analyzed treatment-naïve PDAC patients who underwent preoperative [ Ga]Ga-FAPI-04 PET/CT followed by pancreatectomy. The tracer uptake was determined as maximum tumor standardized uptake value (SUV), FAPI-avid tumor volume (FTV), total lesion FAP expression (TLF) as well total pancreatic uptake (TSUV), total FAPI-avid pancreatic volume (FPV), and total pancreatic FAP expression (TPF).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!